Werewolf Therapeutics files prospectus supplement for up to $25M ATM offering

Werewolf Therapeutics, Inc.

Prospectus supplement filed to sell up to $25M of common stock via Leerink Partners.
Prior $50M ATM program fully exhausted, generating ~$50M in gross proceeds.
Shares outstanding as of Jan 31, 2024: 40,660,732.
Legal opinion from Wilmer Cutler Pickering Hale and Dorr attached as Exhibit 5.1.
Supplement under existing shelf registration (File 333-264844) declared effective May 20, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.